Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodyspla… Read more
Curis Inc (CRIS) - Net Assets
Latest net assets as of September 2025: $-14.69 Million USD
Based on the latest financial reports, Curis Inc (CRIS) has net assets worth $-14.69 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($27.64 Million) and total liabilities ($42.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-14.69 Million |
| % of Total Assets | -53.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | -104.59% |
| 10-Year Change | -109.3% |
| Growth Volatility | 141.99 |
Curis Inc - Net Assets Trend (1999–2024)
This chart illustrates how Curis Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Curis Inc (1999–2024)
The table below shows the annual net assets of Curis Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-6.00 Million | -130.49% |
| 2023-12-31 | $19.67 Million | -57.75% |
| 2022-12-31 | $46.55 Million | -48.68% |
| 2021-12-31 | $90.71 Million | -30.58% |
| 2020-12-31 | $130.67 Million | +485.33% |
| 2019-12-31 | $-33.91 Million | -654.25% |
| 2018-12-31 | $-4.50 Million | -118.74% |
| 2017-12-31 | $23.99 Million | -18.02% |
| 2016-12-31 | $29.27 Million | -54.63% |
| 2015-12-31 | $64.51 Million | +116.60% |
| 2014-12-31 | $29.78 Million | -34.07% |
| 2013-12-31 | $45.17 Million | +31.83% |
| 2012-12-31 | $34.27 Million | -14.06% |
| 2011-12-31 | $39.88 Million | -12.39% |
| 2010-12-31 | $45.52 Million | +37.71% |
| 2009-12-31 | $33.05 Million | -11.21% |
| 2008-12-31 | $37.22 Million | -20.54% |
| 2007-12-31 | $46.84 Million | +30.50% |
| 2006-12-31 | $35.90 Million | -5.53% |
| 2005-12-31 | $38.00 Million | -22.31% |
| 2004-12-31 | $48.91 Million | +25.84% |
| 2003-12-31 | $38.87 Million | +109.60% |
| 2002-12-31 | $18.54 Million | -81.64% |
| 2001-12-31 | $101.02 Million | -40.16% |
| 2000-12-31 | $168.81 Million | +620.76% |
| 1999-12-31 | $23.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Curis Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 111820397600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $85.00K | % |
| Other Components | $1.23 Billion | % |
| Total Equity | $-6.00 Million | 100.00% |
Curis Inc Competitors by Market Cap
The table below lists competitors of Curis Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DIC India Limited
NSE:DICIND
|
$9.74 Million |
|
Global SM Tech Limited
KQ:900070
|
$9.74 Million |
|
Centrale d'Achat Française pour l'Outre-Mer Société Anonyme
PA:CAFO
|
$9.74 Million |
|
DOMIKI KRITIS EO 048
F:F9P
|
$9.75 Million |
|
Youngtimers AG
SW:YTME
|
$9.74 Million |
|
Charnic Capital Tbk PT
JK:NICK
|
$9.74 Million |
|
Tigers Realm Coal Ltd
AU:TIG
|
$9.74 Million |
|
SSH Communications Security Oyj
HE:SSH1V
|
$9.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Curis Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,670,000 to -5,998,000, a change of -25,668,000 (-130.5%).
- Net loss of 43,389,000 reduced equity.
- New share issuances of 12,023,000 increased equity.
- Other comprehensive income decreased equity by 229,000.
- Other factors increased equity by 5,927,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-43.39 Million | -723.39% |
| Share Issuances | $12.02 Million | +200.45% |
| Other Comprehensive Income | $-229.00K | -3.82% |
| Other Changes | $5.93 Million | +98.82% |
| Total Change | $- | -130.49% |
Book Value vs Market Value Analysis
This analysis compares Curis Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $219.27 | $0.89 | x |
| 2000-12-31 | $954.08 | $0.89 | x |
| 2001-12-31 | $317.08 | $0.89 | x |
| 2002-12-31 | $57.47 | $0.89 | x |
| 2003-12-31 | $107.91 | $0.89 | x |
| 2004-12-31 | $114.58 | $0.89 | x |
| 2005-12-31 | $79.04 | $0.89 | x |
| 2006-12-31 | $73.16 | $0.89 | x |
| 2007-12-31 | $85.30 | $0.89 | x |
| 2008-12-31 | $58.73 | $0.89 | x |
| 2009-12-31 | $50.80 | $0.89 | x |
| 2010-12-31 | $60.72 | $0.89 | x |
| 2011-12-31 | $52.23 | $0.89 | x |
| 2012-12-31 | $43.34 | $0.89 | x |
| 2013-12-31 | $54.86 | $0.89 | x |
| 2014-12-31 | $34.64 | $0.89 | x |
| 2015-12-31 | $52.29 | $0.89 | x |
| 2016-12-31 | $22.04 | $0.89 | x |
| 2017-12-31 | $16.09 | $0.89 | x |
| 2018-12-31 | $-2.72 | $0.89 | x |
| 2019-12-31 | $-20.44 | $0.89 | x |
| 2020-12-31 | $53.70 | $0.89 | x |
| 2021-12-31 | $19.81 | $0.89 | x |
| 2022-12-31 | $9.97 | $0.89 | x |
| 2023-12-31 | $3.72 | $0.89 | x |
| 2024-12-31 | $-0.95 | $0.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Curis Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -397.77%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-81.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -51.70% | -377.03% | 0.11x | 1.23x | $-14.45 Million |
| 2000 | -207.54% | -35137.73% | 0.01x | 1.08x | $-367.23 Million |
| 2001 | -81.04% | -7534.60% | 0.01x | 1.43x | $-91.97 Million |
| 2002 | -443.93% | -447.60% | 0.29x | 3.37x | $-84.17 Million |
| 2003 | -29.91% | -105.20% | 0.20x | 1.43x | $-15.51 Million |
| 2004 | -28.43% | -280.75% | 0.07x | 1.38x | $-18.80 Million |
| 2005 | -39.09% | -247.49% | 0.10x | 1.60x | $-18.66 Million |
| 2006 | -24.60% | -59.12% | 0.29x | 1.46x | $-12.42 Million |
| 2007 | -14.87% | -42.49% | 0.30x | 1.15x | $-11.65 Million |
| 2008 | -32.57% | -144.90% | 0.21x | 1.07x | $-15.85 Million |
| 2009 | -29.72% | -114.35% | 0.24x | 1.09x | $-13.13 Million |
| 2010 | -9.74% | -27.72% | 0.32x | 1.11x | $-8.99 Million |
| 2011 | -24.72% | -66.78% | 0.31x | 1.21x | $-13.85 Million |
| 2012 | -47.91% | -96.73% | 0.24x | 2.04x | $-19.84 Million |
| 2013 | -27.28% | -82.14% | 0.19x | 1.78x | $-16.84 Million |
| 2014 | -62.88% | -190.27% | 0.16x | 2.10x | $-21.71 Million |
| 2015 | -91.43% | -748.64% | 0.08x | 1.47x | $-65.43 Million |
| 2016 | -206.42% | -802.59% | 0.13x | 1.97x | $-63.34 Million |
| 2017 | -222.22% | -538.66% | 0.13x | 3.08x | $-55.72 Million |
| 2018 | 0.00% | -312.38% | 0.28x | 0.00x | $-32.13 Million |
| 2019 | 0.00% | -321.28% | 0.28x | 0.00x | $-28.75 Million |
| 2020 | -22.89% | -276.03% | 0.05x | 1.56x | $-42.98 Million |
| 2021 | -50.09% | -426.67% | 0.07x | 1.79x | $-54.51 Million |
| 2022 | -129.58% | -593.62% | 0.09x | 2.34x | $-64.98 Million |
| 2023 | -241.04% | -473.04% | 0.13x | 3.93x | $-49.38 Million |
| 2024 | 0.00% | -397.77% | 0.26x | 0.00x | $-42.79 Million |
Industry Comparison
This section compares Curis Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Curis Inc (CRIS) | $-14.69 Million | -51.70% | N/A | $9.74 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |